Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data

Simply Wall St.2025-12-26

Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2594025039?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-26 07:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594025039","market":"nz","top_or_hot":-1,"title":"Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data","media":"Simply Wall St.","content":"<div>\n<p>Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-valuation-check-after-encouraging-ne\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-26 07:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-valuation-check-after-encouraging-ne><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-valuation-check-after-encouraging-ne\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-valuation-check-after-encouraging-ne","article_id":"2594025039","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-valuation-check-after-encouraging-ne","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594025039","pubTimestamp":1766704867,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately sharpened the stock’s risk reward profile.\nSee our latest analysis for Relay Therapeutics.\nThe zovegalisib update lands after a sharp rebound in sentiment, with a roughly 97 percent 90 day share price return and a 104 percent one year total shareholder return, even though the five year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"Relay Therapeutics(RLAY)：鼓励新的Zovegalisib乳腺癌数据后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1.5},"content_text":"Relay Therapeutics (RLAY) just put fresh clinical data for its PI3K alpha inhibitor zovegalisib in front of oncologists at the San Antonio Breast Cancer Symposium, and the subset analysis immediately sharpened the stock’s risk reward profile. See our latest analysis for Relay Therapeutics. The zovegalisib update lands after a sharp rebound in sentiment, with a roughly 97 percent 90 day share price return and a 104 percent one year total shareholder return, even though the five year total shareholder return remains deeply negative and keeps longer term holders cautious. If this kind of asymmetric setup appeals to you, it could be a good moment to also scan other innovative healthcare stocks that might be poised for their own inflection points. With zovegalisib’s subset data driving fresh enthusiasm and the stock still trading at a hefty discount to analyst targets despite big recent gains, investors now face a pivotal question: is this a genuine buying opportunity, or is the market already pricing in Relay’s next leg of growth? Price-to-Book of 2.5x: Is it justified? On a price-to-book basis, Relay Therapeutics screens as modestly undervalued, with its 2.5x multiple sitting below both the biotech industry and a tighter peer group. Price to book compares the company’s market value to its net assets, which can be a useful reference point for early stage, loss making biotech names where earnings are not yet meaningful. For Relay, this lens highlights how investors are valuing its platform, pipeline and cash against a still substantial accumulated deficit. Relay’s 2.5x price to book ratio sits slightly below the broader US biotech industry average of 2.7x, and meaningfully beneath a peer average of 5.7x, suggesting the market is not assigning a premium despite the strong revenue growth outlook. If sentiment continues to improve around zovegalisib and the wider pipeline, that gap to peers is a level the share price could move toward over time. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to book of 2.5x (UNDERVALUED) However, investors still face meaningful risk from Relay’s steep losses and trial execution, and any clinical setback could quickly compress that current discount to targets. Find out about the key risks to this Relay Therapeutics narrative.  Build Your Own Relay Therapeutics Narrative If you see the numbers differently or want to stress test your own thesis, you can build a personalized Relay view in minutes using Do it your way. A great starting point for your Relay Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? Before this opportunity moves on without you, use the Simply Wall Street Screener to pinpoint focused ideas that match your strategy and sharpen your watchlist.  Capture potential multi baggers early by scanning these 3622 penny stocks with strong financials that pair tiny market caps with surprisingly solid fundamentals. Ride the next productivity wave by targeting these 24 AI penny stocks that apply artificial intelligence to real world problems with meaningful revenue upside. Lock in mispriced quality by zeroing in on these 901 undervalued stocks based on cash flows where strong cash flow support is not yet reflected in the share price.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594025039","isCrawlerRequest":true}